Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 6745 (miR-6745)
- Target
- miR-6745
- Molecular classification
- microRNA, Non-coding RNA, Regulatory RNA
01
Overview
miR-6745 is a human microRNA that acts as a post-transcriptional regulator by binding to the 3'-untranslated region (3'-UTR) of target mRNAs, notably those encoding tissue inhibitor of metalloproteinases 1 (TIMP1). In gastric cancer, miR-6745 expression is decreased, which contributes to tumor progression. Experimental restoration of miR-6745 in cancer cell and mouse models suppresses tumor growth and metastasis by downregulating TIMP1 and inhibiting the canonical Wnt/β-catenin signaling pathway, suggesting its potential utility as a therapeutic target or biomarker for patient prognosis in gastric cancer. Its roles in other tissues and disease settings are not yet well characterized.
- Other names
- hsa-mir-6745microRNA mir-6745MIR6745
02
Mechanism of action
Suppresses oncogenesis by binding to the 3'-UTR of TIMP1 mRNA, leading to its downregulation and subsequent inhibition of Wnt/β-catenin signaling
03
Biological functions
Post-transcriptional regulation of gene expressionTumor suppressionInhibition of cell proliferationInhibition of cell migration and invasionModulation of Wnt/β-catenin signaling pathway
04
Disease associations
Cancer (specifically gastric cancer where it acts as a tumor suppressor)Potential roles in other cancers due to its regulatory nature, though currently direct evidence is limited to gastric cancer
05
Safety considerations
No notable safety concerns or therapeutic challenges directly attributed to manipulation of miR-6745 have been reported in the context of published *in vitro* or *in vivo* models; safety concerns would be expected for any RNA-based therapy but data are lacking.
06
Biomarkers
Low miR-6745 expression in gastric cancer tissue (potential prognostic biomarker for poor outcomes)Negative correlation with TIMP1 protein levels in gastric cancer tissue
Beyond the preview
Go deeper on microRNA 6745 (miR-6745).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 6745 (miR-6745).